Andrea B. Apolo

8.7k total citations · 3 hit papers
194 papers, 4.2k citations indexed

About

Andrea B. Apolo is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrea B. Apolo has authored 194 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Surgery, 93 papers in Oncology and 86 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrea B. Apolo's work include Bladder and Urothelial Cancer Treatments (105 papers), Cancer Immunotherapy and Biomarkers (58 papers) and Urinary and Genital Oncology Studies (53 papers). Andrea B. Apolo is often cited by papers focused on Bladder and Urothelial Cancer Treatments (105 papers), Cancer Immunotherapy and Biomarkers (58 papers) and Urinary and Genital Oncology Studies (53 papers). Andrea B. Apolo collaborates with scholars based in United States, United Kingdom and France. Andrea B. Apolo's co-authors include James L. Gulley, Manish R. Patel, Jeffrey R. Infante, Alain Ravaud, Piyush K. Agarwal, Ding Wang, Carolyn D. Britten, Arnold B. Gelb, Dean F. Bajorin and Michael J. Morris and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andrea B. Apolo

182 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Andrea B. Apolo, James L. Gulley et al. Journal of Clinical Oncology profile →
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 429 citations James L. Gulley, Andrea B. Apolo et al. profile →
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

2022 177 citations Robert J. Motzer, Thomas Powles et al. profile →

Peers

Countries citing papers authored by Andrea B. Apolo

Since Specialization

Citations

This map shows the geographic impact of Andrea B. Apolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea B. Apolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea B. Apolo more than expected).

Fields of papers citing papers by Andrea B. Apolo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea B. Apolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea B. Apolo. The network helps show where Andrea B. Apolo may publish in the future.

Co-authorship network of co-authors of Andrea B. Apolo

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea B. Apolo. A scholar is included among the top collaborators of Andrea B. Apolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea B. Apolo. Andrea B. Apolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HER2 and urothelial carcinoma: current understanding and future directions 2025 ·Nature Reviews Urology ·Daniele Raggi, (unknown), Filippo Pederzoli, Alberto Martini, (unknown), Omar Alhalabi, Peter H. O’Donnell, Jeffrey S. Ross, Shilpa Gupta, Ashish M. Kamat, Bishoy M. Faltas, Peter C. Black, Philippe E. Spiess, Petros Grivas, Jianjun Gao, Andrea B. Apolo, Robert Huddart, Andrea Necchi, Matthew D. Galsky	1
2	Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023) 2025 ·European Journal of Cancer ·Giovanni Maria Iannantuono, Charalampos S. Floudas, Marco Filetti, (unknown), (unknown), (unknown), (unknown), Pasquale Lombardi, (unknown), Elena Giudice, Elisabetta Xue, E. Rapisarda, (unknown), Andrea B. Apolo, Fatima Karzai, Emilio Bria, James L. Gulley, Gennaro Daniele	0
3	Preferred treatment regimens for rare genitourinary (GU) malignancies. 2025 ·Journal of Clinical Oncology ·Nicholas I. Simon, Stephanie Berg, Alan Tan, (unknown), (unknown), (unknown), Lisa M. Cordes, Amir Mortazavi, Melissa A. Reimers, Matthew I. Milowsky, Cora N. Sternberg, Jacob Rosenberg, Matthew D. Galsky, Andrea B. Apolo	0
4	Top advances of the year: Bladder cancer 2025 ·Cancer ·Andrea B. Apolo, (unknown), (unknown), Raju Chelluri, (unknown), Sandeep Gurram, (unknown), Nicholas I. Simon	1
5	A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE). 2024 ·Journal of Clinical Oncology ·(unknown), Nicholas I. Simon, Daniel M. Girardi, Lisa Ley, (unknown), (unknown), (unknown), Salah Boudjadi, (unknown), Elizabeth Smith, (unknown), Scot A. Niglio, Sandeep Gurram, Marijo Bilušić, Seth M. Steinberg, Andrea B. Apolo	0
6	Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma. 2024 ·Journal of Clinical Oncology ·Tito Fojo, Andrea B. Apolo, Maureen Edgerly, Karel Pacák, William D. Figg, Susan E. Bates, Jaydira Del Rivero	2
7	Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial 2024 ·ESMO Open ·Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, (unknown), (unknown), Robert J. Motzer, Toni K. Choueiri	31
8	MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001). 2024 ·Journal of Clinical Oncology ·Shilpa Gupta, Karla V. Ballman, Andrea B. Apolo, Srikala S. Sridhar, Ronald C. Chen, Yujia Wen, Aihua Edward Yen, Petros Grivas, Alan Tan, (unknown), Matt D. Galsky, Michael J. Morris, Jonathan E. Rosenberg	2
9	New Therapeutic Horizons for Advanced or Metastatic Penile Cancer 2024 ·Urologic Clinics of North America ·N. Simon, (unknown), Guru Sonpavde, Andrea B. Apolo	2
10	Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review 2023 ·Clinical Genitourinary Cancer ·(unknown), Patrick W. McGarrah, Alan Paciorek, Amr Mohamed, Andrea B. Apolo, David Chan, Diane Reidy‐Lagunes, (unknown), Jaydira Del Rivero, (unknown), (unknown), Li Zhang, Nitya Raj, (unknown), Emily K. Bergsland, Þorvarður R. Hálfdánarson	5
11	A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies. 2023 ·Journal of Clinical Oncology ·Nicholas I. Simon, Scot A. Niglio, (unknown), Giovanni Maria Iannantuono, Salah Boudjadi, (unknown), Daniel M. Girardi, Lisa M. Cordes, Lisa Ley, Sandeep Gurram, (unknown), Jennifer Jones, Kilian Salerno, Krishnan R. Patel, Vladimir Valera, Howard L. Parnes, William D. Figg, James L. Gulley, Jeffrey Schlom, Andrea B. Apolo	1
12	Understanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: A qualitative interview study with patients, caregivers, and physicians. 2023 ·Journal of Clinical Oncology ·Andrea B. Apolo, Nicholas I. Simon, (unknown), Simrun Grewal, Zsolt Hepp, (unknown), Christine Michaels-Igbokwe, Sebastian Heidenreich, (unknown), John L. Gore	3
13	CT Evaluation of Lymph Nodes That Merge or Split during the Course of a Clinical Trial: Limitations of RECIST 1.1 2021 ·Radiology Imaging Cancer ·(unknown), Mohammadhadi Bagheri, Faraz Farhadi, Andrea B. Apolo, Nadia Biassou, Les Folio, Elizabeth C. Jones, Ronald M. Summers	9
14	696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial 2020 ·Annals of Oncology ·Toni K. Choueiri, Thomas Powles, Mauricio Burotto, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, (unknown), Carlos H. Barrios, Martin Eduardo Richardet, David Pook, Yoshihiko Tomita, Bernard Escudier, (unknown), Burçin Şimşek, Andrea B. Apolo, Robert J. Motzer	85
15	Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies 2017 ·Annals of Oncology ·Rosa Nadal, Amir Mortazavi, Mark N. Stein, Sumanta K. Pal, Nicole N. Davarpanah, Howard L. Parnes, Y. Ning, Lisa M. Cordes, Jeffrey Lin, Mohammadhadi Bagheri, (unknown), (unknown), Seth M. Steinberg, (unknown), (unknown), (unknown), Rene Costello, Donald P. Bottaro, William L. Dahut, Andrea B. Apolo	19
16	Magnetic Nanoparticle Mediated Steroid Delivery Mitigates Cisplatin Induced Hearing Loss 2017 ·Frontiers in Cellular Neuroscience ·Bharath Ramaswamy, Soumen Roy, Andrea B. Apolo, Benjamin Shapiro, Didier A. Depireux	52
17	Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma 2016 ·Bladder Cancer ·Wassim Abida, Matthew I. Milowsky, Irina Ostrovnaya, Scott R. Gerst, Jonathan E. Rosenberg, Martin H. Voss, Andrea B. Apolo, Ashley Marie Regazzi, Asia S. McCoy, Mariel Elena Boyd, Dean F. Bajorin	7
18	Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer 2015 ·European Journal of Radiology ·Les Folio, Evrim Türkbey, Seth M. Steinberg, Andrea B. Apolo	8
19	Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy 2012 ·Current Molecular Medicine ·(unknown), Mehdi Mollapour, (unknown), Shinji Tsutsumi, (unknown), (unknown), Thomas L. Prince, Andrea B. Apolo, Giuseppe Giaccone, Wanping Xu, Len Neckers, Jane B. Trepel	36
20	Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer 2008 ·Journal of Nuclear Medicine ·Andrea B. Apolo, Neeta Pandit‐Taskar, Michael J. Morris	102

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact